Previous studies have reported HER2- (Human epidermal growth factor receptor type 2) positive status in nearly half of all newly diagnosed IBC [9, 10], but few studies have identified HER2 receptor status as a prognostic factor. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.